Neuland Laboratories Ltd logo

Neuland Laboratories Ltd

NEULANDLAB NSE

Key Fundamentals

Volatility
Moderate
P/E Ratio
59.82
EBITDA
₹605 Cr
Return on Equity
19.42%
Debt to Equity
0.16
EPS
₹249.83
52W High
₹23,500
52W Low
₹11,500

Insights

Beta

AI-extracted from concalls & annual reports · figures as reported, with sources

Log in to view Neuland Laboratories Ltd insights

52 extracted metrics + investor summaries across FY15–FY26.

Log in — free

Tapetide Score

Data-driven rating, 0–100. How it works →

Technical Indicators

Key Insights

Strengths

2
  • Company is expected to give good quarter
  • Company has delivered good profit growth of 38.5% CAGR over last 5 years

Weaknesses

2
  • Stock is trading at 15.4 times its book value
  • Promoter holding has decreased over last 3 years: -3.41%

Growth Rate

Revenue Growth
37.13% ↗
Net Income Growth
39.95% ↗
Cash Flow Change
9.22% ↗
ROE
13.83% ↗
ROCE
11.70% ↗
EBITDA Margin (Avg.)
28.27% ↗

AI Analysis — Bull vs Bear

Anthropic anthropic claude-opus-4.6 8d ago
AI opinion · based on fundamentals
Risk high

Neuland Laboratories is a mid-cap CDMO/API player with a market cap of Rs 25,363 Cr trading at a PE of 68x. The company has delivered exceptional TTM sales growth of 78% and profit growth of 278%, though valuations at 13.2x book value reflect significant premium pricing relative to historical norms.

Bull Case 8
  • TTM sales growth of 78% indicates a sharp acceleration in revenue momentum well above the 3-year CAGR of 19%
  • TTM profit growth of 278% demonstrates significant operating leverage kicking in as the business scales
  • 5-year compounded profit CAGR of 39% reflects sustained earnings compounding over a longer horizon
  • ROE of 21% in the last year marks improvement over the 10-year average of 14%, signaling better capital efficiency
  • 3-year ROE of 20% and 5-year ROE of 18% show a consistent upward trajectory in return ratios
  • Stock CAGR of 75% over 3 years reflects strong market recognition of the CDMO opportunity in the API space
  • 10-year compounded sales CAGR of 15% and profit CAGR of 29% show the business has compounded steadily across cycles
  • Company is expected to deliver a good upcoming quarter based on forward indicators, suggesting growth momentum is continuing
Bear Case 8
  • PE ratio of 68x is significantly elevated, pricing in substantial future growth and leaving little margin of safety
  • Price-to-book of 13.2x is expensive for a manufacturing-oriented API business, implying the market expects extraordinary returns on equity going forward
  • Promoter holding has declined by 3.41% over the last 3 years, which may signal insider profit-taking at elevated valuations
  • Dividend yield of only 0.18% offers negligible income, meaning returns are entirely dependent on continued capital appreciation
  • 1-year stock CAGR of 56% after a 3-year CAGR of 75% suggests expectations are heavily front-loaded and vulnerable to any growth disappointment
  • TTM profit growth of 278% is unlikely to be repeatable, creating a high base effect that could make future growth comparisons unfavorable
  • The gap between 5-year sales CAGR of 17% and 5-year profit CAGR of 39% suggests margin expansion may already be largely captured
  • 52-week high and low data unavailable, limiting visibility on recent price range and drawdown risk assessment

This is AI-generated analysis, not financial advice. Do your own due diligence.

AI News Digest

Anthropic anthropic claude-opus-4.6 1d ago
Positives 5
  • PAT surges 975% YoY in Q1 Aug 5

    Net profit jumped 975% YoY to ₹147.4 crore for Q1FY27 with EBITDA rising 448% to ₹231.1 crore. EBITDA margins expanded sharply from 11.78% to 34.74% YoY.

  • ₹398 crore capacity expansion announced Aug 6

    Company announced ₹398 crore investment to expand production capacity at Unit-1 in Bonthapally. Revenue grew to ₹642 crore from ₹293 crore YoY in Q1.

  • Commercial production begins at units Aug 1

    Neuland commenced commercial production of additional capacities at Unit 1 and Unit 3 facilities in Sangareddy District, Telangana.

  • ₹34 dividend, new director appointed Aug 4

    Shareholders approved final dividend of ₹34 per share for FY26 and appointed Dr. Mauricio Futran as Non-Executive Director with overwhelming support.

  • Strategic sterile API partnership Aug 5

    Neuland announced a strategic sterile API partnership with Gland Pharma, complementing its strong Q1 results driven by CMS and GDS businesses.

Neutral 2
  • Emkay Confluence 2026 attendance Aug 7

    Management to participate in Emkay Confluence 2026 in Mumbai on August 12, with group and one-on-one meetings with analysts and institutional investors.

  • Q1FY27 earnings call held Aug 5

    Earnings conference call for quarter ended June 30, 2026 was held on August 5 at 17:30 IST. Audio recording uploaded per SEBI regulations.

TL;DR: Neuland Laboratories delivered an exceptional Q1FY27 with PAT surging ~975% YoY and EBITDA margins expanding to nearly 35%, driven by strong CMS and GDS business momentum. The company is aggressively investing in growth with a ₹398 crore capacity expansion and new commercial production already online. No visible headwinds in recent news flow. The trend is strongly improving with expanding margins, new partnerships, and capacity additions positioning the company for continued growth.

Quarterly Results

  Jun 2023Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Sales
363
418
393
385
440
311
398
328
293
514
440
776
642
Expenses
266
280
272
278
316
249
311
277
258
359
363
469
419
Operating Profit
97
137
121
107
123
62
87
51
34
156
77
307
223
OPM %
27%
33%
31%
28%
28%
20%
22%
16%
12%
30%
18%
40%
35%
Other Income
2
3
2
5
25
4
60
7
8
2
8
12
8
Interest
2
4
4
4
3
1
2
2
5
5
7
7
7
Depreciation
14
15
15
16
16
16
16
17
20
23
24
25
27
PBT
83
122
104
92
130
49
128
39
18
129
54
287
198
Tax %
26%
27%
22%
27%
25%
34%
20%
29%
21%
25%
26%
26%
25%
Net Profit
62
89
81
68
98
33
102
28
14
97
41
213
148
EPS in Rs
48.23
69.56
63.44
52.66
76.28
25.6
79.18
21.68
10.83
75.49
31.62
166
115
Figures in ₹ Crores

Profit & Loss

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026TTM
Sales
469
510
579
527
667
763
937
951
1,191
1,559
1,477
2,023
2,372
Expenses
402
430
472
477
608
661
790
807
918
1,096
1,146
1,443
1,609
Operating Profit
67
80
106
51
58
102
147
144
273
463
331
580
763
OPM %
14%
16%
18%
10%
9%
13%
16%
15%
23%
30%
22%
29%
32%
Other Income
0
2
1
4
3
4
16
0
9
12
90
25
31
Interest
27
24
21
19
16
22
18
14
13
14
8
24
26
Depreciation
15
16
19
22
26
31
40
49
53
60
66
92
98
PBT
25
42
67
14
20
53
105
82
216
401
346
489
669
Tax %
36%
36%
30%
13%
19%
69%
23%
22%
24%
25%
25%
26%
—
Net Profit
16
27
47
12
16
16
81
64
164
300
260
364
498
EPS in Rs
17.96
30.75
52.74
13.57
12.81
12.63
62.85
49.74
127
234
203
284
388
Div. Payout %
8%
7%
0%
0%
0%
16%
8%
10%
8%
6%
6%
12%
—
Figures in ₹ Crores

Balance Sheet

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Equity Capital
9
9
9
9
13
13
13
13
13
13
13
13
Reserves
152
178
537
549
686
697
774
828
981
1,270
1,512
1,862
Borrowings
188
182
192
319
231
264
182
241
128
95
157
301
Other Liabilities
162
155
148
194
200
257
356
302
457
454
498
754
Total Liabilities
512
524
886
1,071
1,130
1,231
1,325
1,383
1,580
1,833
2,180
2,930
Fixed Assets
123
139
466
475
542
653
716
767
758
824
955
1,177
CWIP
41
40
20
126
104
24
17
20
41
46
48
211
Investments
7
7
8
8
8
8
7
4
1
1
109
2
Other Assets
340
337
393
463
476
547
585
592
781
962
1,068
1,541
Total Assets
512
524
886
1,071
1,130
1,231
1,325
1,383
1,580
1,833
2,180
2,930
Figures in ₹ Crores

Cash Flow

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating
13
45
39
11
70
57
189
60
237
261
317
347
Investing
-14
-20
-42
-116
-77
-49
-84
-95
-61
-150
-298
-423
Financing
1
-24
0
105
12
-5
-114
38
-136
-69
25
21
Net Cash Flow
0
1
-4
0
5
3
-9
3
40
42
44
-55
Free Cash Flow
-1
26
-2
-121
7
9
84
-37
173
119
112
-50
CFO/OP
33
70
52
28
128
61
132
56
103
81
119
78
Figures in ₹ Crores

Ratios

  Mar 2015Mar 2016Mar 2017Mar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Debtor Days
100
85
114
134
90
91
85
90
111
87
78
98
Inventory Days
170
182
186
266
191
209
205
227
211
220
238
245
Days Payable
167
121
118
189
118
110
126
100
129
121
156
129
Cash Conversion Cycle
103
147
182
211
162
190
164
216
193
187
160
214
Working Capital Days
11
26
44
38
138
137
60
74
81
88
76
75
ROCE %
16%
18%
16%
4%
4%
8%
11%
10%
21%
33%
19%
26%

Shareholding Pattern

As of Jun 2026
Promoters 32.62%
Public 29.79%
FIIs 21.08%
DIIs 16.52%
Total 100.01%
  Sep 2023Dec 2023Mar 2024Jun 2024Sep 2024Dec 2024Mar 2025Jun 2025Sep 2025Dec 2025Mar 2026Jun 2026
Promoters
35.97%
32.80%
32.74%
32.72%
32.64%
32.68%
32.67%
32.67%
32.64%
32.63%
32.63%
32.62%
FIIs
21.57%
22.69%
24.43%
25.72%
26.46%
23.86%
22.12%
21.69%
20.60%
20.90%
20.46%
21.08%
DIIs
6.99%
6.02%
6.54%
6.39%
6.38%
9.09%
10.97%
11.57%
13.55%
14.72%
15.84%
16.52%
Government
0.40%
0.40%
0.40%
0.40%
0.40%
0.40%
0.40%
0.40%
0.40%
0.00%
0.00%
0.00%
Public
35.08%
38.10%
35.88%
34.77%
34.12%
33.96%
33.85%
33.67%
32.80%
31.76%
31.08%
29.79%
No. of Shareholders
26,824
27,723
28,616
29,077
34,567
39,315
39,333
42,419
44,393
46,187
46,304
44,340

Documents

Frequently Asked Questions about Neuland Laboratories Ltd

What does Neuland Laboratories Ltd do?
Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]
Where is Neuland Laboratories Ltd (NEULANDLAB) listed?
Neuland Laboratories Ltd is listed on the Indian stock exchanges. It is listed on NSE: NEULANDLAB and BSE: 524558. You can view its live share price, financials, and ratios on Tapetide.
Which sector does Neuland Laboratories Ltd belong to?
Neuland Laboratories Ltd operates in the Healthcare sector within the Pharmaceuticals industry. Sector classification helps investors compare companies affected by similar economic conditions and regulatory changes.
What is the PE ratio of Neuland Laboratories Ltd?
The Price-to-Earnings (PE) ratio of Neuland Laboratories Ltd is 59.82. The PE ratio compares a company's share price to its earnings per share and is commonly used to assess whether a stock is overvalued or undervalued relative to its peers.
What is the 52-week high and low of Neuland Laboratories Ltd?
Over the past 52 weeks, Neuland Laboratories Ltd has traded between a low of ₹11,500 and a high of ₹23,500. This range helps investors understand the stock's price volatility and recent trading levels.
What is the Return on Equity (ROE) of Neuland Laboratories Ltd?
Neuland Laboratories Ltd has a Return on Equity (ROE) of 19.42%. ROE measures how effectively a company uses shareholders' equity to generate profits. A higher ROE generally indicates better capital efficiency.
How can I research Neuland Laboratories Ltd on Tapetide?
On Tapetide, you can view Neuland Laboratories Ltd's live share price, quarterly results, profit & loss statements, balance sheet, cash flow, key ratios, shareholding pattern, technical indicators, analyst ratings, and forecasts — all on a single page without needing to sign up.

Company Information

Neuland Laboratories is engaged in manufacturing and selling of bulk drugs and caters to both domestic and international markets.[1]

Website neulandlabs.com
CEO Dr. Davuluri Rama Mohan Rao
Employees 1,794
Listed 2008-10-13
Face Value ₹ 10
Issued Size 1,28,29,889

Explore More

More in Healthcare → FII DII Data Stock Screener Nifty 50 Heatmap F&O Ban List